GLP-1 Market
LLY $1410.99 ▼ -0.5% NVO $40.45 ▲ +1.1% PFE $30.67 ▲ +0.5% VKTX $26.83 ▼ -1.6% KLRA $12.15 ▼ -5.5% GPCR $20.47 ▼ -6.4% RHHBY $60.68 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pitavastatin plus Ezetemibe

Company
Yonsei University
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 3, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pitavastatin plus Ezetemibe and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05705804

    Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial

    Not yet reported Yonsei University 250 participants Est. completion 2028-08-05 1 site Stand-alone
    Cardiovascular disease Other conditions: Dyslipidemias
    View official trial listing →
  • Not yet recruiting NCT NCT07784621

    A Phase 1 Clinical Trial to Evaluate the Safety and the Pharmacokinetic Drug-Drug Interaction Between HUC2A-752-A and HUC2A-752-B in Healthy Adults

    Not yet reported Huons Co., Ltd. 30 participants Est. completion 2027-02 1 site Stand-alone
    Other conditions: Hypertension
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.